Factor VIII inhibitors: a 50-year perspective (Q37876956)

24 August 2017

1 reference

title

Factor VIII inhibitors: a 50-year perspective (English)

1 reference

24 August 2017

D. Green

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A21592257

2 December 2024

language of work or name

English

1 reference

National Center for Biotechnology Information

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=21592257

2 December 2024

publication date

18 May 2011

1 reference

full work available at URL

24 August 2017

https://api.wiley.com/onlinelibrary/tdm/v1/articles/10.1111%2Fj.1365-2516.2011.02568.x

1 reference

DOI

https://api.crossref.org/works/10.1111/J.1365-2516.2011.02568.X

http://onlinelibrary.wiley.com/wol1/doi/10.1111/j.1365-2516.2011.02568.x/fullpdf

2 December 2024

1 reference

DOI

https://api.crossref.org/works/10.1111/J.1365-2516.2011.02568.X

2 December 2024

1 reference

24 August 2017

1 reference

24 August 2017

1 reference

24 August 2017

page(s)

831-838

1 reference

A method for the study of antihaemophilic globulin inhibitors with reference to six cases

24 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2516.2011.02568.X

The immunologic character of acquired inhibitors of antihemophilic globulin (factor 8) and the kinetics of their interaction with factor 8.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2516.2011.02568.X

Non-genetic risk factors and the development of inhibitors in haemophilia: a comprehensive review and consensus report.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2516.2011.02568.X

Inhibitor development: patient-determined risk factors

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2516.2011.02568.X

Rate of inhibitor development in previously untreated hemophilia A patients treated with plasma-derived or recombinant factor VIII concentrates: a systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2516.2011.02568.X

Inhibitors of factor VIII in black patients with hemophilia

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2516.2011.02568.X

Inhibitors of factor VIII in hemophilia

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2516.2011.02568.X

Acquired haemophilia caused by non-haemophilic factor VIII gene variants

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2516.2011.02568.X

Acquired circulating anticoagulants in hemophilia A.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2516.2011.02568.X

Factor VIII-specific B cell responses in haemophilia A patients with inhibitors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2516.2011.02568.X

CD4+FOXP3+ regulatory T cells confer long-term regulation of factor VIII-specific immune responses in plasmid-mediated gene therapy-treated hemophilia mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2516.2011.02568.X

Acquired hemophilia A in the United Kingdom: a 2-year national surveillance study by the United Kingdom Haemophilia Centre Doctors' Organisation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2516.2011.02568.X

Transplacental transfer of postpartum inhibitors to factor VIII.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2516.2011.02568.X

Autoantibodies to coagulation factors

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2516.2011.02568.X

Genetic markers in acquired haemophilia

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2516.2011.02568.X

Increased frequency of the CTLA-4 49 A/G polymorphism in patients with acquired haemophilia A compared to healthy controls

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2516.2011.02568.X

How we treat a hemophilia A patient with a factor VIII inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2516.2011.02568.X

Acquired factor VIII inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2516.2011.02568.X

Immunoadsorption for removal of inhibitors: update on treatments in Malmö-Lund between 1980 and 1995.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2516.2011.02568.X

Immunoadsorption for coagulation factor inhibitors: a retrospective critical appraisal of 10 consecutive cases from a single institution

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2516.2011.02568.X

Activated prothrombin concentrate for patients with factor VIII inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2516.2011.02568.X

Use of human factor VIIa in the treatment of two hemophilia A patients with high-titer inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2516.2011.02568.X

A randomized comparison of bypassing agents in hemophilia complicated by an inhibitor: the FEIBA NovoSeven Comparative (FENOC) Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2516.2011.02568.X

Efficacy of recombinant activated factor VII vs. activated prothrombin complex concentrate for patients suffering from haemophilia complicated with inhibitors: a Bayesian meta-regression

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2516.2011.02568.X

Systematic review of efficacy of rFVIIa and aPCC treatment for hemophilia patients with inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2516.2011.02568.X

Single 270 microg kg(-1)-dose rFVIIa vs. standard 90 microg kg(-1)-dose rFVIIa and APCC for home treatment of joint bleeds in haemophilia patients with inhibitors: a randomized comparison

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2516.2011.02568.X

Randomized, prospective clinical trial of recombinant factor VIIa for secondary prophylaxis in hemophilia patients with inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2516.2011.02568.X

Monitoring rFVIIa 90 μg kg−1 dosing in haemophiliacs: comparing laboratory response using various whole blood assays over 6 h

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2516.2011.02568.X

A highly sensitive thrombin generation assay for assessment of recombinant activated factor VII therapy in haemophilia patients with an inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2516.2011.02568.X

Sequential therapy with activated prothrombin complex concentrates and recombinant FVIIa in patients with severe haemophilia and inhibitors: update of our previous experience

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2516.2011.02568.X

The purification of antihaemophilic globulin from animal plasma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2516.2011.02568.X

Surgery in haemophilia; the use of animal antihaemophilic globulin and human plasma in thirteen cases

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2516.2011.02568.X

The use of porcine factor VIII concentrate (Hyate:C) in the treatment of patients with inhibitor antibodies to factor VIII. A multicenter US experience

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2516.2011.02568.X

Massive factor-VIII infusion in haemophiliac with factor-VIII inhibitor, high responder

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2516.2011.02568.X

Immune tolerance for the treatment of factor VIII inhibitors--twenty years' 'bonn protocol'.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2516.2011.02568.X

Induction of immune tolerance in patients with hemophilia and antibodies to factor VIII by combined treatment with intravenous IgG, cyclophosphamide, and factor VIII.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2516.2011.02568.X

International workshop on immune tolerance induction: consensus recommendations

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2516.2011.02568.X

The international immune tolerance study: a multicenter prospective randomized trial in progress

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2516.2011.02568.X

Treatment of acquired hemophilia A.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2516.2011.02568.X

Successful Treatment of Acquired Hemophilia with Oral Immunosuppressive Therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2516.2011.02568.X

Rituximab for autoimmune haemophilia: a proposed treatment algorithm

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2516.2011.02568.X

Anti-idiotypic suppression of autoantibodies to factor VIII (antihaemophilic factor) by high-dose intravenous gammaglobulin

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2516.2011.02568.X

Anti-idiotypes to factor VIII antibodies and their possible role in the pathogenesis and treatment of factor VIII inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2516.2011.02568.X

Combined prednisolone and intravenous immunoglobulin treatment for acquired factor VIII inhibitors: a 2-year review.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2516.2011.02568.X

International recommendations on the diagnosis and treatment of patients with acquired hemophilia A

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2516.2011.02568.X

Treatment of acquired hemophilia by the Bonn-Malmo Protocol: documentation of an in vivo immunomodulating concept

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2516.2011.02568.X

Rituximab in the treatment of acquired factor VIII inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2516.2011.02568.X

Selective B-cell depletion with rituximab for the treatment of patients with acquired hemophilia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2516.2011.02568.X

Rituximab for the treatment of patients with very high-titre acquired factor VIII inhibitors refractory to conventional chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2516.2011.02568.X

Rituximab and immune tolerance in severe hemophilia A: a consecutive national cohort.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2516.2011.02568.X

Quantitation of anti-factor VIII antibodies in human plasma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2516.2011.02568.X

Loss of high-responder inhibitors in patients with severe hemophilia A and human immunodeficiency virus type 1 infection: a report from the Multi-Center Hemophilia Cohort Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2516.2011.02568.X

Environmental risk factors for inhibitor development in children with haemophilia A: a case-control study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2516.2011.02568.X

Improved hemostasis with superactive analogs of factor VIIa in a mouse model of hemophilia A.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2516.2011.02568.X

Comparative immunogenicity of recombinant B domain-deleted porcine factor VIII and Hyate:C in hemophilia A mice presensitized to human factor VIII.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2516.2011.02568.X

Interleukin-17 and type 17 helper T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2516.2011.02568.X

Th17 immune responses contribute to the pathophysiology of aplastic anemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2516.2011.02568.X

Lineages of human T-cell clones, including T helper 17/T helper 1 cells, isolated at different stages of anti-factor VIII immune responses.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2516.2011.02568.X

Th 17 cells interplay with Foxp3+ Tregs in regulation of inflammation and autoimmunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2516.2011.02568.X

Preventing restimulation of memory B cells in hemophilia A: a potential new strategy for the treatment of antibody-dependent immune disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2516.2011.02568.X

High-dose factor VIII inhibits factor VIII-specific memory B cells in hemophilia A with factor VIII inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2516.2011.02568.X

Antigenic modulation limits the efficacy of anti-CD20 antibodies: implications for antibody selection.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2516.2011.02568.X

A mechanistic rationale for combining alemtuzumab and rituximab in the treatment of ALL.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2516.2011.02568.X

Low-dose rituximab and alemtuzumab combination therapy for patients with steroid-refractory autoimmune cytopenias

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2516.2011.02568.X

Role of anti-idiotypic antibodies in immune tolerance induction

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2516.2011.02568.X

In vivo neutralization of a C2 domain-specific human anti-Factor VIII inhibitor by an anti-idiotypic antibody

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2516.2011.02568.X

Unique strategies for therapeutic gene transfer in haemophilia A and haemophilia BWFH State-of-the-Art Session on Therapeutic Gene Transfer Buenos Aires, Argentina

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2516.2011.02568.X

Lentivirus-mediated platelet-derived factor VIII gene therapy in murine haemophilia A.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2516.2011.02568.X

In vivo efficacy of platelet-delivered, high specific activity factor VIII variants

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2516.2011.02568.X

High-level expression of porcine factor VIII from genetically modified bone marrow-derived stem cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2516.2011.02568.X

Spontaneous inhibitors of factor VIII: kinetics of inactivation of human and porcine factor VIII.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2516.2011.02568.X

An antihaemophilic globulin (factor VIII) inhibitor: purification, characterization and reaction kinetics

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1365-2516.2011.02568.X

Human inhibitor antibodies specific for the factor VIII A2 domain disrupt the interaction between the subunit and factor IXa

2 December 2024

1 reference

https://api.crossref.org/works/10.1111/J.1365-2516.2011.02568.X

The role of intensive plasma exchange in the prevention and management of haemorrhage in patients with inhibitors to factor VIII

2 December 2024

1 reference

https://api.crossref.org/works/10.1111/J.1365-2516.2011.02568.X

Prophylactic Dosing of Anti-Inhibitor Coagulant Complex (FEIBA) Reduces Bleeding Frequency In Hemophilia A Patients with Inhibitors: Results of the Pro-FEIBA Study

2 December 2024

1 reference

https://api.crossref.org/works/10.1111/J.1365-2516.2011.02568.X

Von Willebrand factor-containing factor VIII concentrates and inhibitors in haemophilia A. A critical literature review

2 December 2024

1 reference

https://api.crossref.org/works/10.1111/J.1365-2516.2011.02568.X

Alloantibodies to factor VIII in haemophilia

2 December 2024

1 reference

https://api.crossref.org/works/10.1111/J.1365-2516.2011.02568.X

A Phase II Open-Label Study Evaluating Hemostatic Activity, Pharmacokinetics and Safety of Recombinant Porcine Factor VIII (OBI-1) in Hemophilia A Patients with Alloantibody Inhibitors Directed Against Human FVIII.

2 December 2024

1 reference

https://api.crossref.org/works/10.1111/J.1365-2516.2011.02568.X

2 December 2024

Identifiers

DOI

1 reference

24 August 2017

1 reference